包装 | 价格(元) |
500μg | 电议 |
1mg | 电议 |
Cell experiment: | HEK293 cells (5×104) are seeded in a 96-well plate and transiently cotransfected with the GLP-1R plasmid and the CRE-luciferase reporter plasmid. After a 48 h transfection, different concentrations of GLP-1(1–37) or GLP-1(7–37) are added, and the cells are incubated for 5 h. The cells are harvested for a luciferase assay using a luciferase assay[1]. |
Animal experiment: | Mice[1]The normal KM mice are fasted for 16 h before the administration (i.p.) of GLP-1 and glucose. GLP-1(1-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is given in combination with glucose (4 g/kg). GLP-1(7-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is also administrated in combination with glucose (4 g/kg). The control group is treated with saline (NaCl, 9 g/l) and glucose (4 g/kg). The IPGTT is carried out at 0, 15, 30 and 60 min after glucose and protein administration, and the blood glucose levels are measured as described above[1]. |
产品描述 | Glucagon-like peptide-1 (GLP-1) (1-37) is a 37-residue incretin hormone that is cleaved in vivo into active truncated forms.[1] GLP-1 (1-37) decreases plasma glucose level in high-fat-fed mice when administered at 25 nmol/kg but does not affect plasma insulin level.[2] Pretreament with GLP-1 (1-37) (24 nmol/kg) prevents blood glucose increases in fasted and glucose challenged mice with diabetes induced by streptozotocin.[3] It inhibits polyphagia and polydipsia in STZ-induced diabetic mice 10 and 20 days, respectively, following initiation of GLP-1 (1-37) administration at a dose of 24 nmol/kg. Pretreament with GLP-1 (1-37) (24 nmol/kg) also inhibits loss of pancreatic islets and global and pancreatic oxidative stress in mice with STZ-induced diabetes. |